Biovica International AB Class B (BIOVIC.B) AI Stock Analysis

• Market Cap: kr145.94M
• Dividend Yield: N/A
• Average Volume (3M): 255.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: 18.21%
• EPS Growth: 54.65%
• Country: SE
• Employees: 26
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 210,484,710
• 10 Day Avg. Volume: 434,028
• 30 Day Avg. Volume: 255,382
• PEG Ratio: -0.03
• Price to Book (P/B): 1.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr1.01
• Price Target Upside: 54.76% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: kr0.50 ▼(-23.08%Downside)

Biovica International AB Class B faces significant financial challenges, with strong revenue growth overshadowed by ongoing losses and negative cash flows. The bearish technical indicators further reflect market pessimism. The stock's valuation is constrained by its negative P/E ratio, with no dividend yield to enhance attractiveness. Strategic improvements are necessary to stabilize its financial health.

Biovica International AB Class B Business Overview & Revenue Model

Company Description

Biovica International AB Class B (BIOVIC.B) is a Swedish biotechnology company that specializes in the development and commercialization of innovative diagnostic tests for cancer treatment. The company's flagship product, DiviTum, is a non-invasive blood test used to measure cell proliferation rates, aiding healthcare professionals in monitoring and optimizing cancer therapies. Operating in the healthcare and biotechnology sectors, Biovica focuses on providing solutions that improve patient outcomes and support personalized medicine initiatives.

How the Company Makes Money

Biovica International AB generates revenue primarily through the sale of its diagnostic tests, particularly DiviTum. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to integrate its diagnostic offerings into cancer treatment and clinical trials. Revenue streams include direct sales of test kits, partnerships with laboratories and hospitals for testing services, and licensing agreements. Biovica's growth is also supported by strategic partnerships and collaborations that enhance its market reach and product development capabilities. Additionally, the company's ongoing research and development efforts aim to expand its product portfolio and increase adoption across various markets.

Biovica International AB Class B Financial Statement Overview

Summary

Despite revenue growth, Biovica International AB Class B struggles with consistent losses and negative cash flows. The balance sheet is stable with low leverage, but negative profitability and cash flow issues highlight significant financial challenges.

Income Statement

Biovica International AB Class B shows a substantial revenue growth from SEK 2,045,000 in 2022 to SEK 8,619,000 in 2025, indicating a positive trajectory. However, the company operates with negative EBIT and net income, showing significant losses consistently over the years. Margins remain negative with EBIT and EBITDA margins deteriorating, indicating challenges in profitability despite revenue growth.

Balance Sheet

The company maintains a solid equity base with a high equity ratio, although it has declined as liabilities increased. The debt-to-equity ratio remains low, signaling manageable leverage. However, the negative net income contributes to a negative ROE, reflecting profitability issues. Overall, while the balance sheet is stable, profitability needs improvement.

Cash Flow

Operating cash flows are negative and have worsened over time, reflecting operational challenges. Free cash flow remains negative, with no significant improvements. The company relies on financing activities to sustain operations, which may not be sustainable in the long run without profitability improvements.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	8.62M	7.29M	3.38M	2.04M	2.08M
Gross Profit	8.08M	6.88M	4.62M	4.67M	5.27M
EBITDA	-76.22M	-119.51M	-105.96M	-53.47M	-36.56M
Net Income	-87.62M	-124.82M	-110.49M	-60.00M	-39.48M
Balance Sheet
Total Assets	64.95M	131.41M	172.29M	151.63M	192.65M
Cash, Cash Equivalents and Short-Term Investments	24.41M	79.41M	114.33M	89.79M	145.36M
Total Debt	4.65M	7.83M	10.45M	13.25M	2.42M
Total Liabilities	21.74M	34.77M	33.65M	27.54M	9.99M
Stockholders Equity	43.21M	96.64M	138.63M	124.09M	182.66M
Cash Flow
Free Cash Flow	-85.65M	-114.72M	-97.42M	-55.52M	-37.97M
Operating Cash Flow	-85.37M	-114.58M	-94.64M	-52.13M	-34.41M
Investing Cash Flow	-287.00K	-585.00K	-2.78M	-3.40M	-3.56M
Financing Cash Flow	30.93M	79.50M	122.01M	-136.00K	142.66M

Biovica International AB Class B Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOVIC.B, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.71, below the 50-day MA of 0.71, and below the 200-day MA of 1.35, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 45.89 is Neutral, neither overbought nor oversold. The STOCH value of 47.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BIOVIC.B.

Biovica International AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	kr5.49B	9.89	-63.86%	2.02%	27.11%	26.73%
BIOVIC.B	41 Neutral	kr145.94M	―	-126.57%	―	18.21%	54.65%
NICA	39 Underperform	kr147.56M	―	-180.76%	―	167.59%	48.11%
SPAGO	38 Underperform	kr94.01M	―	-105.78%	―	58.72%	70.69%
BIOSGN	34 Underperform	kr117.41M	―	-56.71%	―	―	35.61%
ACTI	32 Underperform	kr257.10M	―	-186.40%	―	―	24.47%